Envío mundial con seguimiento | Aprox. 9–14 días hábiles

Tu carrito

Tu carrito está vacío

Comenzar a explorar

Envío gratuito en pedidos superiores a €500.

Subtotal€0
Proceder al pago
RendimientoFármaco aprobado

PT-141

Investigación publicada y base de evidencia

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone that acts as a non-selective agonist at melanocortin receptors, with activity at MC4R in central nervous system pathways considered central to its effects on sexual response. It was first investigated as an intranasal agent for erectile dysfunction before being redeveloped as a subcutaneous on-demand injection, and was approved by the FDA in 2019 as Vyleesi for generalised acquired hypoactive sexual desire disorder in premenopausal women. The pivotal RECONNECT phase 3 programme and its open-label extension reported statistically significant but small improvements in desire and reductions in distress, alongside high rates of nausea, flushing and headache. Independent re-analyses and subsequent systematic reviews have debated the clinical magnitude of the effect, and use in men remains investigational.

En resumen
  • PT-141 es un péptido sintético que actúa sobre los receptores de melanocortina.
  • Estudios en mujeres premenopáusicas reportaron pequeños aumentos del deseo sexual.
  • Revisiones independientes cuestionan si las mejoras son clínicamente significativas.

26 estudios · 10 desde 2023 · más reciente 2026

Estudios citados
26
Publicados en 2023+
10
Artículo más reciente
2026
Última revisión
oct 2026

Temas recurrentes en la literatura

  • Melanocortin receptor (MC3R/MC4R) agonism as a central rather than vascular mechanism of sexual response
  • Hypoactive sexual desire disorder in premenopausal women: FDA-approved indication
  • Small effect sizes and contested clinical meaningfulness in independent re-analyses
  • Characteristic tolerability profile: nausea, flushing, headache, transient blood pressure elevation, focal hyperpigmentation with frequent dosing
  • Historic intranasal erectile dysfunction development and renewed interest in male sexual dysfunction
  • Preclinical and in-vitro exploration of melanocortin agonism beyond sexual medicine

Identificadores del compuesto

CAS
189691-06-3
PubChem
9941379

Identidad química

Qué es PT-141, químicamente.

Fórmula molecular
C50H68N14O10
Peso molecular
1025.2 g/mol
Número CAS
189691-06-3
PubChem CID
9941379
También escrito como

Bremelanotide

Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.

La evidencia

26 estudios publicados.

Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.

  1. 01Revisión sistemática2026

    Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov

    Ashour AM, et al. · Frontiers in Medicine · PRISMA-guided systematic review of nine completed registered pharmacological trials for HSDD in adult women

    Flibanserin and bremelanotide were the most extensively studied agents, both acting on central nervous system pathways, and were most often evaluated in phase II/III randomised double-blind placebo-controlled designs in premenopausal women. Endpoint definitions and safety reporting varied substantially between trials, limiting cross-study comparison.

  2. 02Revisión sistemática2026

    Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options

    Toledo RG, et al. · Journal of Minimally Invasive Gynecology · systematic review and meta-analysis, 8994 abstracts screened, 36 included studies (26 randomised controlled trials, 10 single-arm)

    Pooled analysis found that bremelanotide improved desire and arousal outcomes and reduced sexual distress, alongside similar distress reductions for mindfulness-based cognitive behavioural therapy and flibanserin. The authors noted that conclusions for many other interventions could not be drawn because of limited study numbers and heterogeneous outcome measures.

  3. 03Revisión sistemática2024

    Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder

    Spielmans GI · Journal of Sex Research · independent re-analysis of the phase 3 bremelanotide trial data and outcome measures

    The re-analysis reported effect sizes ranging from nil to small across efficacy measures and questioned the validity evidence for several outcome instruments used. The author concluded that most favourable reported outcomes appeared to have been derived post hoc.

  4. 04Revisión sistemática2021

    Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.

    Spielmans GI · J Sex Res · independent meta-analysis of the two phase 3 RECONNECT trials using FDA New Drug Application data

    Efficacy estimates were similar to the sponsor publication, but adverse-event-related discontinuation was substantially higher with bremelanotide (OR 11.98, number needed to harm 6) and participants were less likely to complete the trial and enter the open-label extension than on placebo; the author also reported that most protocol-listed outcomes were not reported in the primary publication.

    Hallazgo de seguridad reportado. Adverse-event-related discontinuation was about twelve-fold higher with bremelanotide than placebo across the phase 3 trials.

  5. 05Clínico humano2022

    Safety Profile of Bremelanotide Across the Clinical Development Program

    Clayton AH, et al. · Journal of Women's Health · integrated safety analysis across 43 phase 1-3 studies, approximately 3500 subjects, dosing up to 18 months

    Pooled analysis reported nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%) and headache (11.3% vs 1.9%) for bremelanotide versus placebo, with no deaths attributed to treatment. Focal hyperpigmentation occurred in more than a third of subjects exposed to consecutive daily dosing, a regimen outside the approved on-demand use.

  6. 06Clínico humano2022

    Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.

    Spana C, et al. · Diabetes Obes Metab · two phase 1 randomised double-blind placebo-controlled trials in premenopausal women with obesity (16-day parallel and 4-day-period crossover)

    Bremelanotide reduced body weight versus placebo (least-squares mean difference -1.3 kg over 16 days in Study A) and reduced caloric intake by roughly 400 kcal/day across both studies.

  7. 07Clínico humano2022

    Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder.

    Thurston L, et al. · J Clin Invest · randomised double-blind placebo-controlled crossover study with psychometrics, functional MRI and hormonal analyses, n=31 premenopausal heterosexual women with HSDD; the abstract names the drug only as MC4R agonism, and the trial's registry entry (NCT04179734) names it as bremelanotide

    MC4R agonism increased sexual desire for up to 24 hours after administration compared with placebo. During functional MRI it enhanced cerebellar and supplementary motor area activity, deactivated the secondary somatosensory cortex in response to visual erotic stimuli, and enhanced amygdala-insula functional connectivity.

  8. 08Clínico humano2022

    Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

    Simon JA, et al. · J Womens Health (Larchmt) · prespecified integrated subgroup analysis of the two RECONNECT phase 3 randomised placebo-controlled trials, n=1202 premenopausal women with HSDD, subcutaneous bremelanotide, 24 weeks

    Bremelanotide improved desire and reduced desire-related distress versus placebo across age, weight, BMI and baseline bioavailable testosterone subgroups, with few exceptions. Desire increased significantly in women not using hormonal contraceptives (a numerical advantage in users), and distress fell regardless of contraceptive use, decreased arousal or HSDD duration.

  9. 09Clínico humano2021

    The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.

    Koochaki P, et al. · J Womens Health (Larchmt) · blinded exit survey (n=242) and telephone interviews (n=80) of RECONNECT phase 3 participants after the double-blind phase

    Women who had received bremelanotide described increased sexual desire, physical arousal and better quality of sexual activity with their partner. Women on placebo described benefits such as positive experiences of seeking treatment and improved partner communication, but not the physiological responses reported with bremelanotide.

  10. 10Clínico humano2019

    Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Kingsberg SA, et al. · Obstetrics and Gynecology · two identical randomised double-blind placebo-controlled phase 3 trials (RECONNECT), 1267 premenopausal women with HSDD, subcutaneous bremelanotide 1.75 mg as needed, 24 weeks

    Bremelanotide produced statistically significant improvements versus placebo in the desire domain score (0.30-0.42, p<.001) and reductions in the desire-related distress score (-0.29 to -0.37, p<=.005). Nausea, flushing and headache were each reported by at least 10% of treated participants.

  11. 11Clínico humano2019

    Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

    Simon JA, et al. · Obstetrics and Gynecology · 52-week open-label extension of the RECONNECT phase 3 trials, 684 enrolled of 856 eligible completers, 272 completed the extension

    Treatment-emergent adverse events during open-label use were nausea (40.4%), flushing (20.6%) and headache (12.0%). Improvements in desire and reductions in distress observed in the core trials were maintained over the extension period.

  12. 12Clínico humano2019

    Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.

    Althof S, et al. · J Sex Med · responder analyses of the phase 2b randomised placebo-controlled dose-finding trial of subcutaneous bremelanotide in premenopausal women with HSDD and/or female sexual arousal disorder

    Minimal clinically important differences derived from the trial data matched thresholds based on expert input. At the dose later taken into phase 3, responder rates on all 7 patient-reported endpoints were significantly higher than with placebo (P ≤ .03).

  13. 13Clínico humano2017

    Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.

    White WB, et al. · J Hypertens · randomised double-blind placebo-controlled parallel trial with ambulatory blood-pressure monitoring, n=397 premenopausal women with normotension or controlled hypertension

    Bremelanotide produced small, transient increases in ambulatory systolic and diastolic blood pressure (about 2-3 mmHg versus placebo in the 0-4 hour post-dose window, peaks typically under 15 minutes) accompanied by reductions in heart rate at the highest dose; discontinuations for prespecified blood-pressure increases were similar across groups.

    Hallazgo de seguridad reportado. Bremelanotide caused small transient rises in blood pressure with a reduction in heart rate after administration.

  14. 14Clínico humano2017

    Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.

    Clayton AH, et al. · Clin Ther · phase 1 randomised double-blind placebo-controlled 3-period crossover, n=24 healthy adults (12 men, 12 women), intranasal bremelanotide with or without oral ethanol over 7 days

    Bremelanotide given with or without ethanol was generally well tolerated, with no clinically significant pharmacokinetic interaction, no significant drug-related hypotensive or orthostatic effects, no increase in treatment-emergent adverse events and no discontinuations for adverse events.

  15. 15Clínico humano2016

    Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

    Clayton AH, et al. · Womens Health (Lond) · phase 2b randomised placebo-controlled dose-finding trial, n=327 premenopausal women with female sexual dysfunction, 12 weeks

    Pooled higher-dose bremelanotide groups showed greater increases than placebo in satisfying sexual events per month and Female Sexual Function Index total score, and greater reductions in Female Sexual Distress Scale-Desire/Arousal/Orgasm score; the most frequent adverse events were nausea, flushing and headache.

  16. 16Clínico humano2006

    An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist

    Diamond LE, et al. · The Journal of Sexual Medicine · randomised placebo-controlled crossover laboratory study, 18 premenopausal women with female sexual arousal disorder, intranasal bremelanotide 20 mg, counterbalanced sessions with neutral and erotic video

    More women reported moderate or high sexual desire after bremelanotide than after placebo (p=0.0114). Among those who attempted intercourse within 24 hours of dosing, a greater proportion reported satisfaction with arousal after bremelanotide (p=0.0256).

  17. 17Clínico humano2005

    Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

    Diamond LE, et al. · Urology · randomised placebo-controlled crossover trial, nineteen men with erectile dysfunction who responded to PDE5 inhibitors, low-dose intranasal PT-141 combined with low-dose sildenafil, RigiScan over 6 hours

    The erectile response to PT-141 plus sildenafil was significantly greater than to sildenafil alone. The combination did not produce new adverse events, or adverse events of greater frequency or severity, than monotherapy.

  18. 18Clínico humano2004

    Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

    Diamond LE, et al. · International Journal of Impotence Research · double-blind placebo-controlled dose-escalation study of intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction, with RigiScan penile rigidity monitoring

    Intranasal PT-141 showed dose-proportional pharmacokinetics with a median Tmax of 0.50 hours and a terminal half-life of approximately 1.85-2.09 hours. Erectile responses were recorded at doses above 7 mg within roughly 30 minutes of dosing; flushing and nausea were the most common adverse events and no maximum tolerated dose was reached.

  19. 19Clínico humano2004

    Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

    Rosen RC, et al. · Int J Impot Res · two phase 1/2 studies of subcutaneous PT-141 with RigiScan monitoring: a dose-ranging study in healthy men without visual sexual stimulation, and a placebo-controlled crossover in men with erectile dysfunction and an inadequate response to sildenafil

    Healthy men showed statistically significant erectile responses above the lowest doses tested. In men with an inadequate sildenafil response, PT-141 produced statistically significant erectile responses at both doses tested during visual sexual stimulation, and it was reported as safe and well tolerated in both studies.

  20. 20Animal in vivo2025

    Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder

    Borland JM, et al. · Neuropharmacology · female Syrian hamsters, receptor mRNA expression analysis plus low- and high-dose bremelanotide in a conditioned sexual reward paradigm

    Melanocortin 3 and 4 receptor mRNA was localised predominantly to ventral tegmental area dopamine neurons. Neither dose of bremelanotide altered receptor expression or conditioned sexual reward in this species, and the authors concluded the drug did not enhance mesolimbic reward circuitry in this model. These are animal findings and do not describe human responses.

  21. 21In vitro2026

    Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors

    Merlino F, et al. · Journal of Medicinal Chemistry · synthesis and receptor pharmacology of 14 mid-size macrocyclic peptide analogues at human melanocortin receptor subtypes

    Compounds FM648 and FM636 were characterised as potent and selective human MC4R antagonists, while FM635 acted as a selective MC4R agonist. The work illustrates ongoing structure-activity optimisation of melanocortin-targeting macrocycles beyond bremelanotide.

  22. 22In vitro2024

    Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression

    Suzuki S, et al. · Anticancer Research · human glioblastoma cell lines treated with bremelanotide, with melanocortin receptor antagonists and forced survivin overexpression as controls

    Bremelanotide reduced survivin expression and induced cell death in glioblastoma cell lines at concentrations non-toxic to control cells, an effect blocked by melanocortin receptor antagonists and by survivin overexpression. This is a cell-culture observation unrelated to any approved clinical indication.

  23. 23Revisión2026

    Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?

    Pfaus JG, et al. · Journal of Clinical Psychopharmacology · narrative commentary reviewing rodent preclinical data, melanocortin-4 receptor neuroanatomy and prior male clinical studies

    The authors argued that existing preclinical and early clinical data support further evaluation of bremelanotide for male arousal and desire disorders, including possible combination with PDE5 inhibitors. No approved male indication exists and the proposed use remains investigational.

  24. 24Revisión2025

    Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions

    Ila V, et al. · Expert Opinion on Pharmacotherapy · narrative review of literature through October 2024 covering PT-141, PnPP-19, L-arginine and L-citrulline

    The review described PT-141 as acting through central melanocortin pathways rather than peripheral nitric oxide signalling. The authors concluded that large-scale trials are still required to establish safety, dosing and any synergistic effect with PDE5 inhibitors.

  25. 25Revisión2025

    Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women

    Barakeh D, et al. · The Annals of Pharmacotherapy · narrative review of pharmacologic management of generalised acquired HSDD in premenopausal women

    The review identified flibanserin and bremelanotide as the only FDA-approved treatments for generalised acquired HSDD in premenopausal women. The authors raised concerns about limited efficacy, adverse effect burden and transparency of the supporting evidence base.

  26. 26Revisión2023

    Targeting the central melanocortin system for the treatment of metabolic disorders

    Sweeney P, et al. · Nature Reviews Endocrinology · mechanistic review of central melanocortin (MC3R/MC4R) signalling and melanocortin-targeting therapeutics

    The review summarised MC4R signalling biology and positioned bremelanotide's 2019 approval as evidence for the tolerability of melanocortin agonist peptides as a therapeutic class, alongside setmelanotide's 2020 approval for syndromic obesity.

Limitaciones

Lo que esta evidencia no establece.

Controlled evidence is confined almost entirely to on-demand subcutaneous dosing for hypoactive sexual desire disorder in premenopausal women, where independent re-analyses dispute whether the statistically significant effects are clinically meaningful; there is no approved or adequately powered indication in men, in postmenopausal women, or for any performance, athletic or cosmetic use. Long-term safety beyond the 52-week open-label extension, cardiovascular outcomes with repeated dosing, and effects of non-approved routes or dose schedules have not been established.

Preguntas comunes sobre la investigación.

What is PT-141?

PT-141, or bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone that acts as an agonist at melanocortin receptors, principally the centrally expressed MC3R and MC4R subtypes.

How does PT-141 relate to Melanotan 2?

PT-141 is an active metabolite of melanotan II, but their receptor profiles differ. Melanotan II retains substantial MC1R activity, the subtype associated in the literature with pigmentation, whereas PT-141 is characterised as having comparatively low MC1R activity and greater relative activity at MC3R and MC4R.

What tolerability signals appear in the published trials?

The phase 3 publications report nausea, flushing, and headache as the most frequently recorded adverse events, along with transient increases in blood pressure and reductions in heart rate following administration. These are trial observations reported for context, not safety guidance.

Disponible en nuestro catálogo

Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.